Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis

Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis

PR Newswire

STOCKHOLM and HANGZHOU, China, Aug 18, 2017 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR) and Ascletis today announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir’s nucleotide polymerase inhibitor for hepatitis C, MIV-802 (Ascletis code: ASC21), in Greater China.

Under the terms of the agreement, Medivir received an upfront payment, and is entitled to receive milestones based on successful development through commercial launch and tiered royalties on net sales of MIV-802 containing products. Ascletis will fund clinical development, manufacturing and commercialization of MIV-802 in Greater China.

“We are pleased to have Ascletis as a partner with their track record in advancing development of pharmaceuticals in Greater China and their portfolio of antivirals with which to create a combination drug against hepatitis C” said Christine Lind, CEO of Medivir.

“Ascletis has filed an NDA in China for its first HCV NS3/4A medicine, danoprevir, at the end of 2016 and has an HCV NS5A inhibitor in the late stage clinical development. By acquiring MIV-802, a nucleotide NS5B inhibitor, Asceltis is committed to treating, eventually eliminating, hepatitis C in greater China with its multiple leading antiviral combinations including MIV-802,” said Dr. Jinzi J. Wu, CEO of Ascletis.

For further information, please contact:
Ola Burmark
CFO Medivir AB
mobile: +46(0)725-480-580

Jianjiong Wang
Associate Director, Corporate Affairs
mobile: +86-181-0650-1929
Email: pr@ascletis.com

About MIV-802

MIV-802 is a potent, pangenotypic nucleotide inhibitor of the HCV NS5B polymerase. Hepatitis C treatments comprise combinations of pharmaceuticals with different antiviral mechanisms. Preclinical data indicate that MIV-802 can be used effectively in combination with other classes of antiviral agents for the treatment of HCV, including protease inhibitors, non-nucleoside NS5B inhibitors, and NS5A inhibitors.

About Medivir

Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

About Ascletis

Ascletis is a leading biotechnology company dedicated to discovering, developing and commercializing new treatments for liver diseases. Ascletis has assembled an entrepreneurial management and senior scientific team with a track record of successful pharmaceutical discovery and development at major global pharmaceutical companies. To date the company has added four late-stage candidates to its product portfolio: Danoprevir (ASC08), an NDA-filed HCV protease inhibitor, licensed from Roche; Ravidasvir (ASC16), phase II completed HCV NS5A inhibitor, licensed from Presidio Pharmaceuticals; ASC06, a clinical stage, first-in-class, RNAi therapeutic for the treatment of liver cancers, licensed from Alnylam Pharmaceuticals; and ASC09, a phase IIa completed HIV protease inhibitor, licensed from Janssen, a Johnson & Johnson company. For more information, please visit www.ascletis.com or www.ascletis.com.cn

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/medivir/r/medivir-licenses-exclusive-rights-to-miv-802-for-greater-china-to-ascletis,c2327980

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/medivir-licenses-exclusive-rights-to-miv-802-for-greater-china-to-ascletis-300506433.html

SOURCE Medivir

SeniorVu Doubles its Partner Communities in Three Months

Logo

SeniorVu Doubles its Partner Communities in Three Months

SoftVu’s Newest Platform Continues Rapid Accelerated Growth

PR Newswire

KANSAS CITY, Mo., Aug. 17, 2017 /PRNewswire/ – SeniorVu announced today it has partnered with over 400 communities since its onset last year.  After announcing it surpassed the 200-mark in April, SeniorVu has accelerated its timeline this summer.

“We are excited to provide a new option to senior living communities,” SoftVu CEO Tim Donnelly said. “Having communities trust us with a new solution, something they’ve been asking for, for years, feels right.”

High-profile communities like Dial Retirement, Overture, and Benchmark are among the 400+ that have partnered with SeniorVu to improve occupancy. New communities are experiencing tours and conversions with the innovative technology.

“At Dial Retirement Communities we put a tremendous amount of value in the time we spend in the selling zone.  We would far rather our sales teams spend more time with fewer leads so we had grown very weary of the amount of time we had to spend sifting through hundreds of leads just to find the one that was qualified and would actually interact with us, giving us a chance to build that relationship that’s so vital during the move-in process,” said Reed Davis, Corporate Director of Sales and Marketing at Dial Retirement Communities. 

“One of the things that we like so much about SeniorVu is that we know the leads we receive are already qualified and ready to interact with us to build that relationship.  We don’t have to make hundreds of calls just to get one person to visit with us about all of the wonderful things we have to offer. It saves my team so much time and it is one of most cost effective marketing strategies I have found.”

Powered by SoftVu, SeniorVu is a state-of-the-art lead generation and marketing automation platform that uses sophisticated machine-learning algorithm technology combined with big data to find future residents for senior living communities. Their team of Family Advocate Managers qualifies those leads and schedules tours for seniors and their adult children who are ready to purchase.

About SoftVu
SoftVu, founded in 1999 and based in Kansas City, accelerates your sales conversion rates by creating, managing, distributing and tracking direct-to-consumer marketing campaigns.  Leveraging big data, machine-learning algorithms and marketing automation, we deliver repeatable and predictable results to our clients, optimizing lead management strategies.

Contact Valissa Smith, VP Strategic Communications
valissa.smith@softvu.com 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/seniorvu-doubles-its-partner-communities-in-three-months-300506295.html

SOURCE SoftVu

Hill Physicians Medical Group Expands Into Grass Valley, California

Hill Physicians Medical Group Expands Into Grass Valley, California

Diversification and expansion plans continue

PR Newswire

SAN RAMON, Calif., Aug. 17, 2017 /PRNewswire/ – Hill Physicians, California’s largest independent physician association, announced it has signed agreements with two large health insurance carriers to offer services in the Grass Valley region.  

Beginning August 1, 2017 Hill Physicians began accepting new members  in Nevada County cities, including Chicago Park, Cedar Ridge, Grass Valley, Penn Valley, Nevada City, North San Juan, Rough and Ready, and Washington. Hill Physicians is contracted to offer both HMO and Medicare products in the region.

“We look forward to serving the Grass Valley community,” said David Joyner, Chief Executive Officer of Hill Physicians Medical Group. “We are in the business of providing access to quality, convenient, local health care through a network of independent physicians.  We are pleased to welcome many well- respected, Nevada County doctors to Hill Physicians Medical Group.”

Over 50 physicians have completed or are in the process of onboarding Hill Physicians’ network and plans to add more physicians are underway. Hill Physicians members will have local access to Dignity Health’s Sierra Nevada Memorial Hospital in Grass Valley.

“We can help doctors and patients realize superior outcomes, because we devote resources that help give doctors more of what they need most – the time to practice medicine,” said Amir Sweha, M.D., Hill Physicians Chief Medical Officer. “We have served the greater Sacramento area for nearly three decades, and look forward to serving the citizens and physicians of Nevada County.”

Hill Physicians is comprised of over 4,000 Northern California healthcare providers, and serves 240,000 HMO members and greater than 100,000 PPO members. Health plan enrollees who select Hill Physicians Medical Group physicians enjoy convenient access to care close to where they live and work.

About Hill Physicians Medical Group
Hill Physicians Medical Group is the largest independent physician association in Northern California and is a nationally known leader in innovative healthcare. The Integrated Healthcare Association and California Association of Physician Groups have recognized Hill Physicians as one of the top-performing medical groups in the state. For more information visit www.HillPhysicians.com.


Contact:

Dan Robinson


Phone:

925.327.6731


Email:


dan.robinson@hpmg.com

 

View original content:http://www.prnewswire.com/news-releases/hill-physicians-medical-group-expands-into-grass-valley-california-300506296.html

SOURCE Hill Physicians Medical Group